2023
Impact of Nicotine Replacement Therapy on Breast Surgery Outcomes
Patel S, Junn A, Sasson D, Dinis J, Duan K, Islam S, Fucito L, Bernstein S, Hsia H. Impact of Nicotine Replacement Therapy on Breast Surgery Outcomes. Journal Of Reconstructive Microsurgery 2023, 40: 239-244. PMID: 37467771, DOI: 10.1055/a-2133-1130.Peer-Reviewed Original ResearchNicotine replacement therapyNRT usageNRT useSurgical complicationsCessation therapyBreast surgeryReplacement therapyEffect of NRTYale New Haven Health SystemMultivariable logistic regression modelBreast surgery outcomesTobacco smoke intakeRetrospective chart reviewType of surgeryBody mass indexSmoking cessation therapyLogistic regression modelsPostoperative complicationsChart reviewPostoperative outcomesSmoke intakeComplication dataMass indexSmoking statusFat necrosisPersonalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes
Ash G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, PMCID: PMC10898917, DOI: 10.1097/jsm.0000000000001078.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringExercise supportHealth informationDigital health informationBody mass indexType 1 diabetesCommunity-based sampleSevere hypoglycemiaMass indexPsychosocial assessmentCGM useHigh satisfaction ratingsPhysician oversightType 1Future interventionsGlucose monitoringMedical readinessMolecular biomarkersBaseline observationsInterventionSatisfaction ratingsAdultsExerciseBehavioral skillsSingle group
2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups